Valuation : Epigenomics AG

Market Cap 798K 930K 747K 684K 1.29M 88.79M 1.29M 8.85M 3.46M 44.75M 3.49M 3.42M 148M P/E 2024
-0.29x
P/E 2025 -2.51x
Enterprise Value 11.77M 13.71M 11.01M 10.09M 19M 1.31B 19.05M 130M 50.99M 660M 51.46M 50.35M 2.18B EV / Sales 2024
-
EV / Sales 2025 490x
Free-Float
70.75%
Yield 2024 *
-
Yield 2025 -
1 day-0.55%
1 week-0.55%
Current month-3.72%
1 month-4.74%
3 months+2.84%
6 months-11.27%
Current year+0.56%
1 week 0.9
Extreme 0.905
0.92
1 month 0.9
Extreme 0.9
1.56
Current year 0.84
Extreme 0.84
1.56
1 year 0.84
Extreme 0.84
1.59
3 years 0.5
Extreme 0.5
3.65
5 years 0.5
Extreme 0.5
25.88
10 years 0.5
Extreme 0.5
1,187.36
Manager TitleAgeSince
Investor Relations Contact - -
Corporate Officer/Principal 55 01/02/2024
Director TitleAgeSince
Chairman 58 01/03/2023
Director/Board Member 55 01/06/2020
Director/Board Member 56 05/02/2024
Date Insider Type Main position Quantity % Market Cap.
29/12/22 Buy

Chief Financial Officer

2,000 0.0122%
07/09/21 Sell

Director

7,790 0.0637%
01/02/21 Buy

Chairman

6,355 0.1079%
Change 5-day change 1-year change 3-year change Capi.($)
-0.55%-0.55%+2.84%-69.83% 930K
+1.07%+3.93%+103.86%+329.22% 4.22B
+2.23%-8.12%+241.32%+34.31% 3.74B
+2.17%+8.28%+58.16%+77.94% 3.64B
+2.75%+11.43%+293.98%+499.77% 2.71B
-2.91%+4.01%-26.20%-20.95% 2.33B
-1.06%+3.18%+32.26% - 1.5B
-5.96%+0.97%+259.23%-19.52% 1.25B
-2.18%+3.80%+19.81%+45.60% 1.05B
+1.68%+22.01%+34.48%+180.72% 694M
Average -0.28%+5.58%+101.97%+117.47% 2.11B
Weighted average by Cap. +0.53%+4.36%+128.00%+165.82%

Financials

2024 2025
Net sales - 24K 27.96K 22.47K 20.57K 38.76K 2.67M 38.87K 266K 104K 1.35M 105K 103K 4.45M
Net income -3.35M -3.9M -3.14M -2.87M -5.41M -373M -5.43M -37.16M -14.53M -188M -14.66M -14.34M -622M -314K -366K -294K -269K -507K -34.94M -509K -3.48M -1.36M -17.61M -1.37M -1.34M -58.27M
Net Debt 10.46M 12.18M 9.79M 8.96M 16.88M 1.16B 16.93M 116M 45.31M 586M 45.73M 44.74M 1.94B 10.97M 12.78M 10.27M 9.4M 17.71M 1.22B 17.76M 122M 47.53M 615M 47.97M 46.93M 2.04B
Logo Epigenomics AG
Epigenomics AG is a Germany-based molecular diagnostics company focused on blood-based detection, prognosis and monitoring of cancers using deoxyribonucleic acid (DNA) methylation technology. It develops and commercializes blood-based diagnostic products across multiple cancer indications. The Company's main product is Epi proColon, a blood test for colorectal cancer screening. Along with the blood-based tests the Company offers services related to research, product development, regulatory approval and manufacturing of in-vitro diagnostic (IVD) products. It also offers Epi proLung, a blood-based test that detects the presence of lung cancer in blood plasma. The Company is present in Europe and the United States.
Employees
3
Date Price Change Volume
28/08/26 0.9050 -0.55% 1,856
27/08/26 €0.9100 -0.55% 0
26/08/26 €0.9150 +0.55% 79
25/08/26 €0.9100 -0.55% 0
24/08/26 €0.9150 +0.55% 5

Annual profits - Rate of surprise